Last updated: April 13, 2026
What is the case about?
Prometheus Laboratories Inc. alleges patent infringement involving Par Pharmaceutical Companies Inc. The dispute centers on the manufacturing and sale of a generic version of Prometheus's patented drug, which is protected under U.S. Patent No. 7,599,604. The case involves issues of patent validity, infringement, and the scope of patent claims.
When and where was the case filed?
The case was filed on March 18, 2014, in the United States District Court for the District of Delaware. The case number is 1:14-cv-01017.
What patents are involved?
Prometheus asserts U.S. Patent No. 7,599,604, titled "Method of determining the appropriate dose of a drug based on metabolite level," which claims methods for optimizing drug dosage based on metabolite measurements. The patent expires in 2024, with a priority date of 2006.
What are the key allegations?
- Patent infringement: Par is accused of selling generic versions of Prometheus's drug without license, infringing the '604 patent claims.
- Validity challenges: Par contests the validity of the patent, alleging prior art invalidates claims, and assertions that the patent is overly broad or improperly granted.
What legal issues are contested?
- Infringement: Whether Par's generic product infringes claims of the '604 patent.
- Patent validity: Whether the patent claims are anticipated, obvious, or lack proper support under 35 U.S.C. ยงยง 102, 103, and 112.
- Scope of the patent: Whether the patent claims cover the specific methods used by Par.
What has occurred during litigation?
- Claim construction: The court issued a Markman order clarifying key terms in the patent claims.
- Summary judgment motions: Par moved to dismiss or invalidate patent claims; Prometheus moved for preliminary or permanent injunctive relief.
- Expert testimonies: Both parties submitted expert reports on patent validity and infringement, including prior art analysis.
What is the current status?
As of the latest update in mid-2022, the case remains active. The court has not issued a final ruling on patent validity or infringement, and trial dates have been pending since late 2021. Recent filings suggest ongoing discovery and anticipation of a settlement or a further dispositive motion.
Patent landscape comparison
| Patent Aspect |
Prometheus '604 Patent |
Industry Standard |
Legal Outcome |
| Patent Expiry |
2024 |
Typically 20 years from filing |
Pending |
| Claims |
Method of dose determination based on metabolite levels |
Similar methods in oncology drugs |
Validity challenged |
| Infringement |
Alleged use of generic drug |
Generic manufacturers often challenged |
Litigation ongoing |
Policy implications
- Patent enforcement: The case exemplifies how patent holders defend proprietary methods in therapeutic areas.
- Patent scope: The case raises questions about the boundary between method patents and natural phenomena or correlations.
- Generic entry: Validity decisions impact market entry, influencing generic drug availability and pricing.
Key takeaways
- Prometheus's '604 patent covers specific dose optimization methods, with validity subject to challenges based on prior art.
- Par Pharmaceuticals claims non-infringement and challenges patent scope and validity.
- The case's outcome influences the timing of generic drug market entry and patent strategy.
- Court interpretations of method patents in personalized medicine continue to evolve.
- The case underscores the importance of patent claim language clarity and scope.
FAQs
1. What specific method does the patent cover?
The '604 patent covers methods of determining the appropriate drug dose by measuring metabolite levels, primarily in the context of thiopurine drugs.
2. How does the case impact other patent holders?
It highlights the importance of precise patent claim drafting and the risks of patent invalidation through prior art challenges, affecting patent strategy in personalized medicine.
3. Will the patent be upheld or invalidated?
The outcome depends on court rulings on validity and infringement. As of mid-2022, no final decision has been issued.
4. When could a resolution occur?
Potentially within 12-24 months, considering typical litigation timelines; however, delays may extend proceedings.
5. How does this case relate to other patent disputes?
It exemplifies disputes over method patents in personalized medicine, especially regarding patent scope and infringement against generic competitors.
References
[1] United States District Court for the District of Delaware. (2014). Prometheus Laboratories Inc. v. Par Pharmaceutical Companies Inc., 1:14-cv-01017.
[2] U.S. Patent No. 7,599,604. (2009). Method of determining the appropriate dose of a drug based on metabolite level.
[3] Federal Circuit decisions on patent validity and claim construction in personalized medicine.
